Sanan IC Expands Wafer Foundry Portfolio for Power Electronics with 150mm GaN-on-Silicon Process
SUNNYVALE, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced the commercial release of its 150mm gallium nitride (GaN) on silicon wafer foundry services intended for the latest high voltage AC/DC and DC/AC power electronics applications in the global market. Sanan IC’s new G06P111 is a 650V enhanced-mode high-electron-mobility transistor (E-HEMT) GaN process which adds to the company’s power electronics wafer foundry portfolio of wide bandgap (WBG) compound semiconductors that includes 100mm and 150mm silicon carbide (SiC) for high voltage Schottky Barrier Diodes (SBD). Leveraging years of high volume GaN manufacturing experience by Sanan Optoelectronics Inc., its parent company, for the LED market, Sanan IC is able to complement its foundry services with in-house MOCVD growth capabilities of high voltage, low leakage GaN-on-silicon epitaxial wafers with high uniformity.
“The launch of our 650V GaN E-HEMT process technology exemplifies our commitment to advanced compound semiconductor manufacturing for serving the global market”, said Jasson Chen, Assistant General Manager of Sanan IC. “We view GaN-on-silicon as a complimentary technology to silicon carbide as key wide bandgap semiconductors of choice for today’s high voltage, high power electronics industry. Component suppliers and system designers are migrating to wide bandgap semiconductors over traditional silicon for enhanced performance, efficiency, and reliability in high power analog designs. Sanan IC is well positioned for success in serving this high growth, large-scale power electronics market”.
The company’s G06P11 GaN-on-silicon process, having passed the JEDEC standard for process reliability qualification, offers device structures for 650V E-mode FETs which support a drain-to-source on-state resistance RDS(on) range from 50mΩ to 400mΩ. Engineered for low leakage, low gate charge, high current density, and low dynamic specific on resistance (Rsp), it enables ultra-fast switching compact designs for high temperature operation. Following later this year would be the launch of a 200V GaN E-HEMT process as well as a second generation SiC SBD process with a merged PiN Schottky (MPS) diode structure.
GaN-on-silicon as a process technology is ideal for the latest wave of consumer and server applications such as power adapters, USB-PD (power delivery), portable chargers, and power factor correction (PFC) for AC/DC uninterrupted power supplies (UPS). The technology is also getting traction in other markets such as EV/HEV (hybrid/electric vehicles), LiDAR, and wireless charging. According to Yole Développement (Yole), a leading technology market research firm, part of Yole Group of Companies, the GaN power device market is forecasted to have a value over $423M by 2023 with a compound annual growth rate (CAGR) of 93% from 2017 to 2023 1 . Sanan IC is dedicated to serving this emerging technology for these multiple market segments in the power electronics industry.
1 This bull case scenario has been developed by Yole Développement (Yole) within a report, entitled “Power GaN 2018: Epitaxial, Devices, Applications, and Technology Trends report, December 2018”.
About Sanan IC
Sanan Integrated Circuit Co., Ltd. (Sanan IC) is China’s first 6-inch compound semiconductor wafer foundry, serving the microelectronics and photonics markets worldwide. The company was founded in 2014, and is based in Xiamen City in the Fujian Province of China, operating as a subsidiary of Sanan Optoelectronics Co., Ltd. (SSE: 600703). The company develops and provides GaAs, GaN, SiC, and InP foundry services with its state-of-the-art III-V compound semiconductor fabrication facilities. Certified to the ISO9001 international quality standard, ISO14001 environmental management standard, and IATF 16949:2016 Automotive Quality Management System (QMS) standard, Sanan IC empowers the global community of RF, millimeter wave, filter, power electronics, and optical communications markets with its advanced process technology platform. Sanan IC is Dedicated to Drive Compound Semiconductor Innovation. www.sanan-ic.com/en.
Media Relations Contact
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Scanship Holding ASA : Invitation to 3Q2019 Trading update on Tuesday 22 October14.10.2019 21:52:00 CEST | Press release
Welcome to Scanship Holding ASA's 3Q2019 Trading update at hrs. 12.00 on Tuesday 22 October in Oslo. With the recent acquisition of ETIA, Scanship has significantly broadened and expanded its adressable market, and the presentation will include more insight to forward growth strategies within the various landbased markets. Special attention will be given on Scanship's value proposition for the European biogas market and within chemical recycling of plastic waste. The presentation will be held at MESH in Tordenskioldsgate 3, and a light lunch will be served. Please notify Scanship by e-mail to attend: email@example.com, or cell + 47 928 88 728 Venue: MESH, the Lounge, Tordenskiolds gate 3, 0160 Oslo For further queries, please contact: Henrik Badin - CEO Scanship Holding ASA Tel: +47 90 78 98 25 Email: firstname.lastname@example.org ABOUT SCANSHIP HOLDING ASA Scanship delivers world leading solutions for cleaner oceans in the Cruise and Aquaculture industries. Scanship provides advan
Notice of extraordinary general meeting in Oasmia Pharmaceutical AB14.10.2019 20:48:00 CEST | Press release
The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. The registration opens at 13:30 CET. NOTICE OF ATTENDANCE Shareholders who wish to participate in the general meeting must be recorded in the share register kept by Euroclear Sweden AB as of Wednesday 30 October 2019 and give notice of intent to participate to the Company no later than on Wednesday 30 October 2019, either by letter to Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, Sweden, by facsimile: +46 (0)18-51 08 73 or by e-mail: email@example.com, and specify the number of advisors (maximum two). If shareholder’s attendance and right at the meeting will be exercised by proxy, we would be grateful if such is provided in connection with the notification of attendance. A proxy form is available to shareholders upon request and is avaliable at the Comp
Kallelse till extra bolagsstämma i Oasmia Pharmaceutical AB14.10.2019 20:48:00 CEST | Pressemelding
Aktieägarna i Oasmia Pharmaceutical AB (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 6 november 2019 kl. 14:00, i Bolagets lokaler, Vallongatan 1, 752 28 Uppsala. Inregistrering påbörjas kl. 13:30. ANMÄLAN Aktieägare som önskar delta vid bolagsstämman skall dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 30 oktober 2019, dels anmäla sitt deltagande till Bolaget senast onsdagen den 30 oktober 2019 under adress Oasmia Pharmaceutical AB, Vallongatan 1, 752 28 Uppsala, per fax: 018-51 08 73 eller via e-post: firstname.lastname@example.org, varvid antalet biträden skall anges (högst två). Om deltagande skall ske med stöd av fullmakt är vi tacksamma om sådan ges in redan i samband med anmälan. Fullmakten får inte vara äldre än ett år gammal, dock att fullmakten får vara äldre än ett år om det framgår att den är giltig för en längre period, längst fem år. Fullmaktsformulär tillhandahålls aktieägare på begäran och finns tillgängligt hos Bolaget och på Bolagets we
The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million14.10.2019 20:46:00 CEST | Press release
The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 million (the “Rights Issue”). The proceeds from the Rights Issue will primarily be used to finance and accelerate the commercialization of Apealea® and capture new business opportunities based on the Company's proprietary XR17 platform. Moreover, Oasmia intends to create a stable financial position enabling a solid platform for growth. The Company’s major shareholder Per Arwidsson through Arwidsro Investment AB and related parties (“Arwidsro”) has undertaken to subscribe for its pro-rata share in the Rights Issue, corresponding to approximately SEK 100 million or 25 percent. Oasmia has also received a financing commitment from Arwidsro enabling Oasmia to repay the convertible loan on 31 October
Styrelsen i Oasmia föreslår en företrädesemission om cirka 400 MSEK14.10.2019 20:46:00 CEST | Pressemelding
Styrelsen i Oasmia Pharmaceutical AB (”Oasmia” eller ”Bolaget”) offentliggör idag kallelse till extra bolagsstämma den 6 november 2019. Bolagsstämman föreslås besluta att bemyndiga styrelsen att genomföra en företrädesemission om cirka 400 MSEK (”Företrädesemissionen”). Likviden från Företrädesemissionen ska huvudsakligen användas för att finansiera och accelerera kommersialiseringen av Apealea® samt tillvarata nya affärsmöjligheter baserade på Bolagets egenutvecklade XR17-plattform. Därutöver avser Oasmia att skapa en stabil finansiell position för att möjliggöra framtida tillväxt. Bolagets största aktieägare Per Arwidsson via Arwidsro Investment AB och närstående (”Arwidsro”) har åtagit sig att teckna sig för sin pro rata-andel i Företrädesemissionen, motsvarande cirka 100 MSEK eller 25 procent. Oasmia har också fått ett finansieringsåtagande från Arwidsro som möjliggör för Oasmia att återbetala det utestående konvertibellånet den 31 oktober 2019. Sammanfattning Styrelsen offentliggö
Arion Bank: Discontinued operations and assets held for sale have negative impact on Q3 2019 financial results14.10.2019 20:29:00 CEST | Press release
Discontinued operations and assets held for sale will have a negative impact of approximately ISK 3 billion after tax on Arion Bank’s Q3 2019 financial results, compared with a loss of ISK 715 million in Q2 2019. Discontinued operations held for sale refer to assets or companies which the Bank intends to sell in the next few months and are placed below net earnings from continuing operations in the income statement. Increased losses in the quarter are attributable to three factors: As a result of the challenging markets, including the low global price of silicon, Arion Bank is making an impairment of ISK 1.5 billion in respect of assets owned by Stakksberg. Stakksberg is a holding company for the silicon plant at Helguvík which is in the process of being sold. Preparations to sell the plant have been ongoing and an environmental impact assessment has been commissioned and new agreements with energy companies negotiated. Due to difficult conditions in the travel industry, Arion Bank is